• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Boehringer Ingelheim GmbH Market Share Analysis - Product Image

Boehringer Ingelheim GmbH Market Share Analysis

  • ID: 1146920
  • January 2013
  • 70 pages
  • GlobalData

FEATURED COMPANIES

  • Bayer HealthCare AG
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc
  • Novartis AG
  • Pfizer Inc.
  • MORE

Boehringer Ingelheim GmbH Market Share Analysis

Summary

Our new report, “Boehringer Ingelheim GmbH Market Share Analysis” provides in-depth information on Boehringer Ingelheim GmbH’s market position in the different medical equipment markets it operates in. The report provides Boehringer Ingelheim GmbH market share information in one key market category – Metered Dose Inhaler Devices. The report also provides data and information on the overall competitive landscape of the markets, the company operates in. The report is supplemented with global corporate-level profile with information on the company’s business segments, major products and services, competitors, locations and subsidiaries, financial deals and other key developments.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts.

Scope

- Global company shares (in Revenues) information for the key markets Boehringer Ingelheim GmbH operates in – Drug Delivery Devices.
- Boehringer Ingelheim GmbH’s company shares (in Revenues) information READ MORE >

FEATURED COMPANIES

  • Bayer HealthCare AG
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc
  • Novartis AG
  • Pfizer Inc.
  • MORE

1
1

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 What Is This Report About?
3 Definitions of Markets/Categories Covered
3.1 Drug Delivery Devices
3.1.1 Metered Dose Inhaler Devices
4 Company Snapshot
4.1 Key Facts
4.2 Company Overview
4.3 SWOT Snapshot
5 Business Description
5.1 Business Overview
5.2 Animal Health
5.2.1 Overview
5.2.2 Financials
5.2.3 Market View
5.3 Human Pharmaceuticals
5.3.1 Overview
5.3.2 Financials
5.3.3 Market View
5.4 Human Pharmaceuticals
5.4.1 Overview
5.4.2 Financials
5.4.3 Market View
5.5 Major Products and Services
5.5.1 Overview
6 History
7 Business Strategy
7.1 Mission Statement
8 SWOT Analysis
8.1 Overview
8.2 Boehringer Ingelheim GmbH Strengths
8.2.1 Delivering Value through Innovation
8.2.2 Geographical Diversity
8.2.3 Contract Manufacturing Capabilities
8.2.4 Broad Product Portfolio
8.3 Boehringer Ingelheim GmbH Weaknesses
8.3.1 Pradaxa Lawsuit
8.3.2 Product Recalls
8.4 Boehringer Ingelheim GmbH Opportunities
8.4.1 Strategic Alliances
8.4.2 Market Growth in Emerging Economies
8.4.3 Growing CRO Industry
8.5 Boehringer Ingelheim GmbH Threats
8.5.1 Increased Scrutiny on Imports
8.5.2 Stringent Government Regulations
8.5.3 Uncertain R&D Outcomes
8.5.4 Cost Containment Pressures
9 Competitors
10 Competitive Landscape
10.1 Drug Delivery Devices (Metered Dose Inhaler Devices), Global, Market Share (%), 2011
10.2 Boehringer Ingelheim GmbH, Market (Metered Dose Inhaler Devices), by Region, Market Share (2011)
10.3 Boehringer Ingelheim GmbH, Drug Delivery Devices (Metered Dose Inhaler Devices), by Country, Market Share (2011)
11 Key Employees
12 Key Employee Biographies
13 Company Statement
14 Locations And Subsidiaries
14.1 Head Office
14.2 Other Locations & Subsidiaries
15 Financial Deals Landscape
15.1 Boehringer Ingelheim GmbH, Deals Volume Summary, 2007 to YTD 2013
16 Boehringer Ingelheim GmbH Detailed Deal Summary
16.1 Partnerships
16.1.1 BioGenes Enters Into Co-Development Agreement With Boehringer Ingelheim
16.2 Equity Offering
16.2.1 Vectura Group Completes Private Placement Of $7.22 Million
16.2.2 Boehringer Ingelheim Completes Private Placement Of Bonds For $1,250.5 Million
17 Recent Developments
17.1 Strategy And Business Planning
17.1.1 Sep 17, 2012: Boehringer Ingelheim To ShutDown One API Plant In Petersburg, Virginia
17.1.2 Sep 10, 2012: Boehringer Ingelheim Implements Flexible Fully Disposable Up- And Downstream Manufacturing For Biopharmaceuticals
17.1.3 Jun 18, 2012: Boehringer Ingelheim Sets Up Distinctive Brand For Biopharmaceutical Contract Manufacturing Business
17.1.4 May 31, 2012: Boehringer Ingelheim Expands Development Capacities With New Technical Center
17.1.5 Mar 12, 2012: Boehringer Ingelheim Sets Up First Asian Veterinary Research & Development Center In Shanghai
17.1.6 Dec 14, 2011: Boehringer Ingelheim Significantly Expands Supply Center For China
17.1.7 Sep 26, 2011: Boehringer Ingelheim Expands Business With Biosimilars
17.1.8 Jun 20, 2011: Boehringer Ingelheim Expands New Service With New Fill And Finish Capabilities
17.1.9 Feb 15, 2011: Pfenex And Boehringer Ingelheim Sign Non-Exclusive Strategic Agreement For Use Of Pfenex Expression Technology
17.1.10 Nov 27, 2009: Boehringer Ingelheim, Vectura Terminate Collaboration
17.1.11 Nov 09, 2009: Evotec Extends Research Collaboration With Boehringer Ingelheim
17.1.12 Oct 22, 2009: Evotec Obtains E2.5m Milestone Payment From Boehringer Ingelheim
17.1.13 Jun 15, 2009: Boehringer Ingelheim, Vitae Collaborate For Development Of Beta-Secretase Inhibitors
17.1.14 May 29, 2009: Boehringer Ingelheim, DxS Sign Collaboration Agreement
17.1.15 Jun 17, 2008: Boehringer Ingelheim To Acquire Actimis Pharmaceuticals
17.1.16 Apr 19, 2006: Vectura Enters Agreement With Boehringer Ingelheim
17.2 Financial Announcements
17.2.1 Aug 14, 2012: Boehringer Ingelheim Achieves Growth In H1 2012
17.2.2 Apr 24, 2012: Boehringer Ingelheim Reports Net Sales Of €13.2 Billion In 2011
17.2.3 Aug 09, 2011: Boehringer Ingelheim Reports Net Sales Of €6.4 Billion For H1 2011
17.2.4 Jul 28, 2009: Boehringer Ingelheim Posts First Half Financial Results
17.2.5 Aug 07, 2008: Boehringer Reports 1H 2008 Results
17.2.6 Jul 26, 2007: Boehringer Declares H1 2007 Results
17.3 Research And Development
17.3.1 Sep 19, 2012: Ten Pharmaceutical Companies Unite To Accelerate Development Of New Medicines
17.3.2 Jul 09, 2012: Boehringer Ingelheim Establishes Translational Research Collaboration With Harvard University In Areas Of Unmet Medical Need
17.3.3 Feb 29, 2012: Boehringer Ingelheim Expands Capabilities In Biopharmaceutical Process Science
17.3.4 Feb 03, 2012: Boehringer Ingelheim, GWT And TU Dresden Sign Diabetes Research Collaboration
17.3.5 Jan 17, 2012: CompleGen Announces Successful Delivery Of XenoGene Technology To Boehringer Ingelheim Under Non-Exclusive Agreement
17.3.6 Jan 05, 2012: FORMA Therapeutics Announces Collaboration With Boehringer Ingelheim For Development Of New Oncology Drugs
17.3.7 Feb 16, 2011: Québec Consortium for Drug Discovery Launches New Explore Program To Drive Innovation
17.3.8 Nov 22, 2010: f-star And Boehringer Ingelheim Partner To Develop New Therapeutic Antibodies
17.3.9 Oct 26, 2010: Boehringer Ingelheim Partners With MacroGenics To Discover, Develop And Commercialize DART-Based Antibody Therapeutics
17.3.10 Aug 26, 2010: Boehringer Ingelheim Opens Center of Competence In Shanghai
17.4 Corporate Communications
17.4.1 Jun 26, 2008: Boehringer Ingelheim Announces Board Changes
17.5 Government and Public Interest
17.5.1 Sep 12, 2012: Common Application For HIV Patient Assistance Program Expedites Application Process For Lifesaving Drugs
17.5.2 Oct 23, 2009: EMEA Issues Positive Opinion For Micardis
17.5.3 Oct 14, 2009: Boehringer Ingelheim Receives Marketing Authorisation From European Commission For Mirapexin/Sifrol
17.5.4 Oct 07, 2009: Astellas, Boehringer Ingelheim Reach Settlement With Impax
17.6 Product News
17.6.1 Oct 01, 2012: Boehringer Ingelheim’s New Project Transfer Program Enables Fast Track To Launch For Biopharmaceuticals
17.7 Other Significant Developments
17.7.1 Oct 26, 2012: Boehringer Ingelheim To Invest €85m In Dortmund Facility To Double Respimat Production
17.7.2 Apr 25, 2012: Boehringer Ingelheim Standardizes All Prescription Medicine Commercial Teams Worldwide On Cloud-Based, Veeva CRM And iRep
17.7.3 Apr 20, 2012: Boehringer Ingelheim Launches GLORIA-AF Registry Program To Investigate Use Of Antithrombotic Therapy
17.7.4 Jan 26, 2012: Boehringer Ingelheim Launches Lean-to-Clinic Program For Fast Drug Product Supply
17.7.5 Oct 20, 2011: Patheon Signs Three Year $18m Development Agreement With Boehringer Ingelheim
18 Appendix
18.1 Research Methodology
18.2 Secondary Research
18.3 Primary Research
18.4 Models
18.5 Forecasts
18.6 Expert Panels
18.7 Consulting
18.8 Currency Conversion
18.9 Contact Us
18.10 Disclaimer

1.1 List of Tables
Table 1: Boehringer Ingelheim GmbH, Key Facts
Table 2: Boehringer Ingelheim GmbH, SWOT Analysis, 2011
Table 3: Drug Delivery Devices (Metered Dose Inhaler Devices), Global, Company Share by Revenue ($m), 2011
Table 4: Boehringer Ingelheim GmbH, Market (Metered Dose Inhaler Devices), by Region, Revenue ($m) and Market Share (%), 2011
Table 5: Boehringer Ingelheim GmbH, Drug Delivery Devices (Metered Dose Inhaler Devices), by Country, Revenue ($m) and Market Share (%), 2011
Table 6: Boehringer Ingelheim GmbH, Key Employees
Table 7: Boehringer Ingelheim GmbH, Subsidiaries
Table 8: Boehringer Ingelheim GmbH, Deals Volume Summary, 2007 to YTD 2013
Table 9: Boehringer Ingelheim GmbH, Deals Summary, 2007 to YTD 2013
Table 10: BioGenes Enters Into Co-Development Agreement With Boehringer Ingelheim
Table 11: Vectura Group Completes Private Placement Of $7.22 Million
Table 12: Boehringer Ingelheim Completes Private Placement Of Bonds For $1,250.5 Million
Table 13: USD to Local Currency, Average Exchange Rate, 2011

1.2 List of Figures
Figure 1: Drug Delivery Devices (Metered Dose Inhaler Devices), Global, Market Share (%), 2011
Figure 2: Boehringer Ingelheim GmbH, Market (Metered Dose Inhaler Devices), by Region, Market Share (%), 2011
Figure 3: Boehringer Ingelheim GmbH, Drug Delivery Devices (Metered Dose Inhaler Devices), by Country, Market Share (%), 2011
Figure 4: Boehringer Ingelheim GmbH, Deals Volume Summary, 2007 to YTD 2013

Novartis AG
Bristol-Myers Squibb Company
Pfizer Inc.
F. Hoffmann-La Roche Ltd.
Merck & Co., Inc
Bayer HealthCare AG

Note: Product cover images may vary from those shown

RELATED PRODUCTS